Date: 2018-06-28
Type of information: Nomination
Compound: member of the board of directors
Company: Sangamo Therapeutics (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 28, 2018, Sangamo Therapeutics announced the appointment of Dr. Karen Smith, an accomplished drug development executive, to the company's Board of Directors. Dr. Smith has over 20 years of biopharmaceutical industry experience in the United States, Europe, Canada and Asia. She has overseen more than 50 clinical trials and more than 20 regulatory approvals leading to global product launches of small molecules, biologics and devices. Most recently, she served as Executive Vice President, Global Head R&D, and Chief Medical Officer of Jazz Pharmaceuticals
- . Prior to joining Jazz in 2015, Dr. Smith served as Senior Vice President, Global Medical Affairs and Global Dermatology Head for Allergan. From 2008 to 2011, she held leadership positions in External Medical Relations and Global Development at AstraZeneca, and from 2002 to 2008 she held various senior management and clinical roles with Bristol-Myers Squibb, including Head of U.S. Clinical Operations.
- Dr. Smith currently is a member of the Board of Directors of Acceleron Pharma and a Board Advisor for the Australian Philanthropic 'Eliminate Cancer' Initiative. She received a B.App.Sc. in Biotechnology and a B.Sc. in Haematology from Curtin University of Technology, an M.D. from the University of Warwick, her Ph.D. in Oncology Molecular Genetics from the University of Western Australia, an M.B.A. from the University of New England in Australia, and a Master of Laws (L.L.M.) in Health Law from the University of Salford.
Financial terms:
Latest news:
Is general: Yes
